ALK+ALCLs induce cutaneous, HMGB-1-dependent IL-8/CXCL8 production by keratinocytes through NF-κB activation

被引:32
作者
Dejean, Emilie [1 ]
Foisseau, Marianne [1 ]
Lagarrigue, Frederic [2 ]
Lamant, Laurence [1 ,3 ]
Prade, Nais [4 ]
Marfak, Abdelghafour [5 ]
Delsol, Georges [1 ]
Giuriato, Sylvie [1 ,3 ]
Gaits-Iacovoni, Frederique [2 ]
Meggetto, Fabienne [1 ,3 ]
机构
[1] Univ Toulouse 3, Ctr Rech Cancerol Toulouse, INSERM, UMR 1037, F-31062 Toulouse, France
[2] Univ Toulouse 3, Inst Malad Metab & Cardiovasc, INSERM, UMR 1048, F-31062 Toulouse, France
[3] European Res Initiat Anaplas Large Cell Lymphomas, Vienna, Austria
[4] Hop Purpan, CHU Toulouse, Hematol Lab, Toulouse, France
[5] Univ Limoges, CHU Dupuytren, CNRS, UMR 6101, Limoges, France
关键词
LARGE-CELL LYMPHOMA; KINASE NPM-ALK; DOWN-REGULATION; TYROSINE KINASE; INFLAMMATION; CANCER; EXPRESSION; HMGB1; PROTEIN; SKIN;
D O I
10.1182/blood-2011-10-386011
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Anaplastic large-cell lymphomas (ALCLs) bearing the t(2;5) translocation (ALK(+)ALCLs) are frequently characterized by skin colonization and associated with a poor prognosis. Using conditional transgenic models of anaplastic lymphoma kinase-positive (ALK(+)) lymphomas and human ALK(+)ALCL cell lines, in the present study, we show that high-mobility-group box-1 (HMGB-1), a proinflammatory cytokine, is released by ALK(+)cells, and demonstrate extracellular HMGB-1-stimulated secretion of the IL-8 chemokine by HaCaT keratinocytes through the involvement of MMP-9, PAR-2, and the NF-kappa B pathway. Furthermore, we demonstrate that, in vitro, IL-8 is able to induce the invasiveness of ALK(+)cells, which express the IL-8 receptors CXCR1 and CXCR2. In vitro and in vivo, HMGB-1 inhibition achieved by glycyrrhizin treatment led to a drastic reduction in ALK(+)cell invasiveness. The pathophysiological relevance of our observations was confirmed by demonstrating that the HMGB-1 and IL-8 receptors are expressed in ALK(+)ALCL biopsies. We have also shown that IL-8 secretion is correlated with leukemic dissemination of ALK(+)cells in a significant number of patients. The results of the present study demonstrate for the first time a relationship among the proinflammatory mediators HMGB-1, MMP-9, PAR-2, and IL-8. We propose that these mediators create a premetastatic niche within the skin, thereby participating in ALK(+)lymphoma epidermotropism. (Blood. 2012; 119(20):4698-4707)
引用
收藏
页码:4698 / 4707
页数:10
相关论文
共 44 条
[1]
Glycyrrhizin prevents of lipopolysaccharide/D-galactosamine-induced liver injury through down-regulation of matrix metalloproteinase-9 in mice [J].
Abe, Kazuki ;
Ikeda, Tadayuki ;
Wake, Kenjiro ;
Sato, Tetsuji ;
Sato, Toshitsugu ;
Inoue, Hideo .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2008, 60 (01) :91-97
[2]
[Anonymous], 2008, WHO CLASSIFICATION T
[3]
Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer [J].
Arora, Puneeta ;
Ricks, Tiffany K. ;
Trejo, JoAnn .
JOURNAL OF CELL SCIENCE, 2007, 120 (06) :921-928
[4]
DAMPs, PAMPs and alarmins: all we need to know about danger [J].
Bianchi, Marco E. .
JOURNAL OF LEUKOCYTE BIOLOGY, 2007, 81 (01) :1-5
[5]
Bonvini P, 2002, CANCER RES, V62, P1559
[6]
NORMAL KERATINIZATION IN A SPONTANEOUSLY IMMORTALIZED ANEUPLOID HUMAN KERATINOCYTE CELL-LINE [J].
BOUKAMP, P ;
PETRUSSEVSKA, RT ;
BREITKREUTZ, D ;
HORNUNG, J ;
MARKHAM, A ;
FUSENIG, NE .
JOURNAL OF CELL BIOLOGY, 1988, 106 (03) :761-771
[7]
High mobility group box-1 recognition: The beginning of a RAGEless era? [J].
Branco-Madeira, Filipe ;
Lambrecht, Bart N. .
EMBO MOLECULAR MEDICINE, 2010, 2 (06) :193-195
[8]
Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome [J].
Briot, Anais ;
Deraison, Celine ;
Lacroix, Matthieu ;
Bonnart, Chrystelle ;
Robin, Aurelie ;
Besson, Celine ;
Dubus, Pierre ;
Hovnanian, Alain .
JOURNAL OF EXPERIMENTAL MEDICINE, 2009, 206 (05) :1135-1147
[9]
Delsol G., 2008, WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, P312
[10]
EPSTEIN AL, 1974, CANCER-AM CANCER SOC, V34, P1851, DOI 10.1002/1097-0142(197412)34:6<1851::AID-CNCR2820340602>3.0.CO